| 93.45 -2.3 (-2.4%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 118.41 | 1-year : | 138.3 |
| Resists | First : | 101.37 | Second : | 118.41 |
| Pivot price | 98.01 |
|||
| Supports | First : | 91 | Second : | 84.58 |
| MAs | MA(5) : | 97.01 |
MA(20) : | 96.28 |
| MA(100) : | 93.3 |
MA(250) : | 96.55 |
|
| MACD | MACD : | 1.7 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 41.7 |
D(3) : | 62.8 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 113.56 | Low : | 84.58 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZBH ] has closed below the lower bollinger band by 7.4%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 95.33 - 96.11 | 96.11 - 96.63 |
| Low: | 91.3 - 92.16 | 92.16 - 92.73 |
| Close: | 92.33 - 93.65 | 93.65 - 94.54 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Thu, 05 Mar 2026
CHF67.50 pre-market 05 Mar 2026: ZBH.SW Zimmer Biomet volume spike signals test - Meyka
Wed, 04 Mar 2026
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Update - MarketBeat
Wed, 04 Mar 2026
Zimmer Biomet (ZBH) Valuation Check As AAOS 2026 Robotics And Smart Implant Showcase Nears - simplywall.st
Wed, 04 Mar 2026
Victory Capital Management Inc. Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Mon, 02 Mar 2026
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating Growth with a Potential 4.28% Upside - DirectorsTalk Interviews
Sat, 28 Feb 2026
Zimmer Biomet’s Robotics and Smart Knee Push Might Change The Case For Investing In ZBH - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 198 (M) |
| Shares Float | 197 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 9,790 (K) |
| Shares Short P.Month | 10,330 (K) |
| EPS | 3.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 64.43 |
| Profit Margin | 8.5 % |
| Operating Margin | 20.5 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 5.5 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 29.97 |
| Sales Per Share | 41.52 |
| EBITDA (p.s.) | 13.42 |
| Qtrly Earnings Growth | -41.3 % |
| Operating Cash Flow | 1,700 (M) |
| Levered Free Cash Flow | 1,490 (M) |
| PE Ratio | 26.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.45 |
| Price to Sales | 2.25 |
| Price to Cash Flow | 10.89 |
| Dividend | 0.23 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|